Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias

CONCLUSIONS: We discovered novel variant of the oncoprotein CIP2A and its clinical relevance in predicting tyrosine kinase inhibitor therapy resistance in myeloid leukemias.PMID:33674272 | DOI:10.1158/1078-0432.CCR-20-3679

Source: Clinical Cancer Research - March 6, 2021 Category: Cancer & Oncology Authors: Eleonora Makela Karolina Pavic Taru M Varila Urpu Salmenniemi Eliisa L öyttyniemi Srikar G Nagelli Tea Ammun ét Veli-Matti K ähäri Richard E Clark Laura L Elo Venkata Kumari Bachanaboyina Claire M Lucas Maija It älä-Remes Jukka Westermarck Source Type: research